1500 per cent dividend declared: Stocks hits fresh 52-week high mark on stellar results!

1500 per cent dividend declared: Stocks hits fresh 52-week high mark on stellar results!

Vaishnavi Chauhan
/ Categories: Trending, Mindshare, Dividend

The stock has experienced significant buying activity, yielding returns of more than 24 per cent in the last 1 year.

Today, the shares of Divis Laboratories Limited soared by 2.84 per cent to reach a fresh 52-week high mark of Rs 4,387 on the BSE. Furthermore, the scrip witnessed a massive spurt in volume by more than 1.16 times. The company's current market capitalization standing at Rs 1,16,142.50 crore.

Stock performance:

On Tuesday, the stock opened at Rs 4250, with the previous closing being Rs 4254. The 52-week high and low are Rs 4,387 and Rs 3,300, respectively as per BSE.

Recent Development – Financial Highlights:

In the financial year 2023-24, Divi's Laboratories recorded a consolidated total income of Rs 8,184 crore, which is slightly higher than the previous year's income of Rs 8,112 crore. However, the Profit Before Tax (PBT) for the current year decreased to Rs 2,163 crore from Rs 2,369 crore in the previous year. Similarly, the net profit for the year stood at Rs 1,600 crore, down from the previous year's PAT of Rs 1,824 crore.

Despite the decrease in profits, the Board of Directors has proposed a dividend of Rs 30 per share of face value Rs 2 each i.e., 1,500 per cent for the financial year 2023-24.

DSIJ's 'Large Rhino' service recommends blue chip stocks of Large Cap companies that have leadership positions in their category. If this interests you, do download the service details here.

About the Company:

Established in 1990, Divis Laboratories Ltd specializes in the manufacturing and export of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical ingredients.

Divis Laboratories Ltd's product-wise breakdown reveals that APIs constitute 54 per cent of its portfolio, while Custom Synthesis accounts for 46 per cent.

Furthermore, in terms of location-wise distribution, Europe emerges as the primary market, representing 40.13 per cent of the company's operations. The USA follows closely behind at 28.87 per cent, with Asia Pacific comprising 13.63 per cent. India holds a significant share at 11.46 per cent.

Furthermore, the stock has experienced significant buying activity, yielding returns of more than 24 per cent in the last 1 year.

 

Disclaimer: The article is for informational purposes only and not investment advice.

Previous Article 3:1 Bonus Share & FIIs took a fresh entry in this low PE, high ROE & high ROCE multibagger pharma stock under Rs 80; PAT zooms over 500 per cent
Next Article Heavy buying and 350 per cent returns: Back-to-back upper circuit in this multibagger stock; hit fresh 52-week high!
Rate this article:
5.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR